ATC code None CAS Number 606143-89-9 ChemSpider 8463660 Molar mass 441.23 g/mol | Legal status Investigational PubChem CID 10288191 KEGG D10604 | |
 | ||
Binimetinib vs dacarbazine in nras mutant melanoma
Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.
Contents
- Binimetinib vs dacarbazine in nras mutant melanoma
- Dr reinhard dummer on toxicities with binimetinib in metastatic melanoma
- Mechanism of action
- Development
- References
It can be taken orally in tablet form.
Dr reinhard dummer on toxicities with binimetinib in metastatic melanoma
Mechanism of action
Binimetinib is an inhibitor of mitogen-activated protein kinase kinase (MEK), or more specifically, a MAP2K inhibitor. MEK is part of the RAS pathway, which is involved in cell proliferation and survival. MEK is upregulated in many forms of cancer.
Development
In 2015, it was in phase III clinical trials for ovarian cancer, BRAF mutant melanoma, and NRAS Q61 mutant melanoma.
In December 2015, the company announced that the mutant-NRAS melanoma trial was successful. In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment. NDA submitted Jun 2016, and the FDA should decide by 30 June 2017.
In April 2016, it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.
Binimetinib was studied for treatment of rheumatoid arthritis, but a phase II trial did not show benefit.